Rohan Garje, MD

Rohan Garje, MD, discusses clinical outcomes among patients with invasive primary urethral cancer based on varying treatment approaches and histology.

Rohan Garje, MD, discusses the unmet needs for patients with small cell bladder cancer.

Rohan Garje, MD, discusses the benefits of a multimodal approach for patients with small cell bladder cancer.

Rohan Garje, MD, discusses the impact of human papillomavirus status on survival outcomes in penile squamous cell carcinoma.

Rohan Garje, MD, discusses emerging biomarkers in metastatic castration-resistant prostate cancer and where the treatment field is headed.

Rohan Garje, MD, discusses the utility of lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer.

Rohan Garje, MD, discusses considerations when choosing between FDA-approved PARP inhibitor–based combinations for patients with mCRPC.

Rohan Garje, MD, discusses the evolving use of genomic testing and targeted treatment approaches in prostate cancer.